American Journal of Cardiology
Volume 105, Issue 8 , Pages 1102-1106 , 15 April 2010

Use of Non-Steroidal Antiinflammatory Drugs and Type-Specific Risk of Acute Coronary Syndrome

  • Héctor Bueno, MD, PhD

      Affiliations

    • Department of Cardiology, Hospital General Universitario “Gregorio Marañón,” Madrid, Spain
    • Corresponding Author InformationCorresponding author: Tel: 34-91-5868293; fax: 34-91-5868276
    • ,
  • Alfredo Bardají, MD, PhD

      Affiliations

    • Servicio de Cardiología, Hospital Universitari de Tarragona Joan XXIII, IISPV, Universitat Rovira i Virgili, Tarragona, Spain
    • ,
  • Paola Patrignani, PhD

      Affiliations

    • Department of Medicine, Center of Excellence on Aging, G. d'Annunzio University, School of Medicine, CeSI, Chieti, Italy
    • ,
  • Elisa Martín-Merino, BPharm

      Affiliations

    • Centro Español de Investigación Farmacoepidemiológica, Madrid, Spain
    • ,
  • Luis A. García-Rodríguez, MD

      Affiliations

    • Centro Español de Investigación Farmacoepidemiológica, Madrid, Spain
    • ,
  • Spanish Case-Control Study to Assess NSAID-Associated ACS Risk Investigators

Received 5 October 2009 ,Revised 3 December 2009 ,Accepted 3 December 2009.

References 

  1. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? (Meta-analysis of randomised trials). BMJ. 2006;332:1302–1308
  2. García Rodríguez LA, Varas-Lorenzo C, Maguire A, González-Pérez A. Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population. Circulation. 2004;109:3000–3006
  3. Chan AT, Manson JE, Albert CM, Chae CU, Rexrode KM, Curhan GC, et al. Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation. 2006;113:1578–1587
  4. Hernández-Díaz S, Varas-Lorenzo C, García Rodríguez LA. Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction. Basic Clin Pharmacol Toxicol. 2006;98:266–274
  5. Helin-Salmivaara A, Virtanen A, Vesalainen R, Grönroos JM, Klaukka T, Idänpään-Heikkilä JE, et al. NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland. Eur Heart J. 2006;27:1657–1663
  6. García Rodríguez LA, Taconnelli ST, Patrignani P. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol. 2008;52:1628–1636
  7. Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest. 2006;116:4–15
  8. García-Dorado D, Castro-Beiras A, Díez J, Gabriel R, Gimeno-Blanes JR, Ortiz de Landázuri M, et al. Cooperative Cardiovascular Disease Research Network (RECAVA). Rev Esp Cardiol. 2008;61:58–65
  9. Lanas A, García-Rodríguez LA, Arroyo MT, Gomollon F, Feu F, Gonzalez Perez A, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective COX-2 inhibitors, traditional non-aspirin NSAIDs, aspirin, and combinations. Gut. 2006;55:1731–1738
  10. Clive DM, Stoff JS. Renal syndromes associated with nonsteroidal antiinflammatory drugs. N Engl J Med. 1984;310:563–572
  11. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? (A meta-analysis). Ann Intern Med. 1994;121:289–300
  12. Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an unrecognized public health problem. Arch Intern Med. 2000;160:777–784
  13. Solomon DH, Glynn RJ, Rothman KJ, Schneeweiss S, Setoguchi S, Mogun H, et al. Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups. Arthritis Rheum. 2008;59:1097–1104
  14. Patrono C, Coller B, Dalen J, Fuster V, Gent M, Harker L, et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest. 2004;126:234S–264S
  15. Capone ML, Tacconelli S, Sciulli MG, Grana M, Ricciotti E, Minuz P, et al. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation. 2004;109:1468–1471
  16. Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA American Heart Association. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation. 2007;115:1634–1642
  17. Watson DJ, Rhodes T, Cai B, Guess HA. Lower risk of thromboembolic events with naproxen among patients with rheumatoid arthritis. Arch Intern Med. 2002;162:1105–1110
  18. Rahme E, Pilote L, LeLorier J. Association between naproxen use and protection against acute myocardial infarction. Arch Intern Med. 2002;162:1111–1115
  19. Capone ML, Tacconelli S, Sciulli MG, Anzellotti P, Di Francesco L, Merciaro G, et al. Human pharmacology of naproxen sodium. J Pharmacol Exp Ther. 2007;322:453–460

 This study was funded through an unrestricted grant from Pfizer, S.A., Madrid, Spain.

PII: S0002-9149(09)02836-7

doi: 10.1016/j.amjcard.2009.12.008

American Journal of Cardiology
Volume 105, Issue 8 , Pages 1102-1106 , 15 April 2010

Article Tools